Acadia Healthcare

At the Jefferies conference Acadia Healthcare said demand for behavioral health services remains strong while the company works to convert the 3,000 beds opened since 2023 into stable earnings and cash flow. Management cited receivable write-offs, claim denials and start-up losses as near-term headwinds but is confident it can realize about $200 million of incremental EBITDA through accreditations, contract negotiations with payers and higher occupancy. CEO Debbie Osteen promised a “return to basics” and tight execution; one new facility already reached break-even in about a year. The company reports stabilized daily revenues, improved employee retention and expects pressure from receivable write-offs to ease over the course of the year. » Więcej na de.investing.com

KeyBanc has raised its price target for Acadia Healthcare to 40 USD, driving the stock on high volume. The reason is growing occupancy rates in the psychiatric clinics and ongoing capacity expansions. Analysts see further substantial upside for the U.S. clinic operator against the backdrop of the mental-health megatrend. » Więcej na finanzen.net

Acadia Healthcare’s stock rose to a 52-week high of $32.82, gaining 43.92% over the past year. Over the past six months the price increased by 165%, and year-to-date by 123%. Analyst updates, including upgrades from Jefferies and affirmed overweight ratings from KeyBanc, highlight operational improvements under new management and further growth potential. An InvestingPro analysis currently rates the stock as undervalued and sees additional upside potential. » Więcej na de.investing.com